Results 111 to 120 of about 8,127 (167)

Hepatitis B Reactivation During Ribociclib Therapy in a Patient with Metastatic Breast Cancer. [PDF]

Turk J Gastroenterol
Demiral YE, Günegül Y, Eminler AT, Tozlu M, Uslan Mİ.   +4 more
europepmc   +1 more source

Vitiligo-Like Hypopigmentation Induced by Ribociclib in a Patient With Metastatic Breast Cancer. [PDF]

Cureus
El Ghazouli I, Gallouj S, El Jouari O.
europepmc   +1 more source

Cardiovascular toxicity of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in HR+/HER2- breast cancer: a real-world study based on the FAERS database. [PDF]

Front Pharmacol
Ma S, Li L, Chen Y, Zhao Y.
europepmc   +1 more source

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. [PDF]

Curr Oncol
Abdel-Razeq H, Sharaf B.
europepmc   +1 more source

Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Kim E, Lim Y, Ham A, Kim HG, Lee JW, Lee JH, Woo J, Lim W, Moon BI, Ahn SH, Lee HA, Lee KE.   +11 more
europepmc   +1 more source

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review. [PDF]

Cancer Chemother Pharmacol
João RB, Soares LR, Ragazzo PC, Freitas-Junior R.   +3 more
europepmc   +1 more source

Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India. [PDF]

PLoS One
Mukherjee A, Goyal P, Tripathi R, Goyal S, Batra U, Talwar V, Goel V, Jain A, Saha S, Bothra S, Agrawal C, Chugh S, Doval DC.   +12 more
europepmc   +1 more source

[Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay]. [PDF]

Rev Med Inst Mex Seguro Soc
Camejo-Martínez N, Strazzarino-Peluffo N, Amarillo-Hernández C D, Castillo-Leska C, Krygier-Waltier G.   +4 more
europepmc   +1 more source

Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma. [PDF]

Transl Oncol
Gloege HF, De Los Santos MAIC, Chakraborty A, Chadha M, Aguilar-Quintero A, Shen M, Heaslip CO, Finstuen-Magro S, McDannell B, Tanhaemami M, Meyer S, Klega K, Zhang YQ, Shulman DS, DuBois SG, Hall MD, Blandin AF, Crompton BD.   +17 more
europepmc   +1 more source

Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR⁺/HER2^- advanced breast cancer. [PDF]

Am J Cancer Res
Hou B, Zhang Y.
europepmc   +1 more source